Is Asia RNA- Ready for Commercial Scale RNA Manufacturing?
RNA therapeutics and vaccines have transitioned from experimental platforms to commercially viable technologies. The success of mRNA vaccines during the COVID-19 pandemic catalysed global investment into RNA research, manufacturing infrastructure, and supply chains.
APAC has emerged as a rapidly expanding RNA ecosystem. Governments are investing in domestic manufacturing capability, biotech startups are advancing clinical pipelines, and CDMOs are expanding nucleic acid services.
Overview of RNA Therapeutics
RNA therapeutics represent a class of medicines that use ribonucleic acid (RNA) to prevent or treat disease by directing cellular protein expression.
Major RNA modalities include:
mRNA (Messenger RNA)
Used to instruct cells to produce therapeutic proteins or antigens. Widely applied in vaccines and oncology.
siRNA (Small Interfering RNA)
Silences disease-causing genes by degrading specific mRNA sequences.
saRNA (Self-Amplifying RNA)
Amplifies within cells to produce higher protein output from smaller doses.
Circular RNA (circRNA)
A more stable RNA structure under investigation for long-lasting protein expression.
Therapeutic Areas Expanding in APAC:
- Infectious diseases
- Oncology
- Rare genetic disorders
- Protein replacement therapies
- Immunotherapy platforms
As pipelines expand into later-stage development, manufacturing scalability becomes critical.
The RNA Manufacturing Value Chain
Commercial RNA production requires a fully integrated ecosystem.
Raw Materials & Critical Inputs
Key materials include:
- Nucleotides
- Enzymes
- Cap analogues
- Ionisable lipids
- Plasmid DNA templates
Challenge:
Supply of ionisable lipids and specialised reagents remains concentrated in North America and Europe.
APAC Status:
Regional suppliers are emerging, but import dependency remains significant.
RNA Synthesis (In-Vitro Transcription – IVT)
RNA is produced through enzymatic transcription using DNA templates.
Commercial scale requires:
- Large-batch IVT systems
- Process optimisation
- High-yield production
- Reproducibility across batches
Scaling IVT while maintaining purity and consistency is technically complex.
Purification & Process Development
Downstream purification removes:
- Double-stranded RNA impurities
- Residual enzymes
- DNA fragments
Technologies include:
- Chromatography systems
- Filtration systems
- Process analytical technologies
Vendor Opportunity:
Advanced purification platforms remain in high demand.
Formulation & Lipid Nanoparticle (LNP) Systems
RNA requires delivery systems to protect and transport molecules into cells.
LNP formulation determines:
- Stability
- Efficacy
- Safety profile
LNP access is one of the most significant bottlenecks in APAC.
Fill-Finish & Packaging
RNA products require:
- Sterile aseptic filling
- Cold-chain distribution
- Specialised storage
APAC has strong fill-finish capacity in India, China, and South Korea, but RNA-specific adaptation is still scaling.
Quality Control & Release Testing
RNA-specific analytical testing includes:
- RNA integrity assays
- Potency testing
- Encapsulation efficiency
- Particle size distribution
- Stability studies
Many biologics labs are not yet equipped for RNA-specific assays.
APAC Country Readiness Assessment
Singapore has positioned itself as a regional centre for advanced biologics and RNA manufacturing.
Investments from companies such as Moderna have strengthened regional infrastructure.
Strengths:
- Strong regulatory environment
- Skilled workforce
- Stable supply chain access
Readiness Level: High
South Korea hosts major CDMOs including Samsung Biologics.
Government initiatives promote vaccine independence and advanced therapy expansion.
Strengths:
- Large-scale GMP facilities
- Strong biologics manufacturing experience
Readiness Level: High–Moderate
Companies such as Daiichi Sankyo are developing mRNA platforms.
Strengths:
- Mature regulatory system
- Advanced R&D ecosystem
Readiness Level: Moderate–High
China has seen rapid growth in RNA development.
Companies including Stemirna Therapeutics are advancing mRNA pipelines.
CDMOs such as WuXi AppTec are expanding nucleic acid services.
Strengths:
- Government support
- Domestic ecosystem depth
Challenges:
- Export restrictions
- International regulatory alignment
Readiness Level: High (domestic focus)
India has strong vaccine manufacturing capabilities.
Gennova Biopharmaceuticals achieved domestic approval for an mRNA vaccine.
Strengths:
- Large fill-finish capacity
- Cost-efficient manufacturing
- Strong generics infrastructure
Challenges:
- Limited proprietary LNP platforms
Readiness Level: Moderate–High
Australia is investing in domestic mRNA manufacturing infrastructure.
Strengths:
- Government funding
- Academic-commercial partnerships
Readiness Level: Emerging
The Role of CDMOs
CDMOs are essential to scaling RNA manufacturing.
Leading players expanding into nucleic acid services include:
- WuXi AppTec
- AGC Biologics
- Samsung Biologics
CDMOs provide:
- Process development.
- GMP manufacturing.
- Analytical development.
- Technology transfer.
- Multi-product platform capabilities.
Their scalability determines how quickly RNA therapeutics move from clinical to commercial scale.
Key Challenges to Commercial-Scale Readiness
Vendor Opportunity Landscape
SUSTAINABILITY & ESG CONSIDERATIONS IN APAC RNA MANUFACTURING
As APAC scales RNA manufacturing capacity, sustainability is becoming a strategic priority rather than a secondary compliance requirement.
Emerging expectations across the region include:
Green IVT Chemistry Optimisation
Improving in vitro transcription (IVT) efficiency to reduce reagent consumption, solvent use, and waste generation. Process intensification and higher-yield enzymatic systems will be key to lowering environmental footprint at scale.
Reduction of Single-Use Plastic Waste
RNA manufacturing relies heavily on single-use systems. APAC CDMOs are increasingly evaluating:
- Recyclable single-use materials.
- Hybrid stainless-steel systems.
- Waste recovery and circular disposal partnerships.
Cold Chain Carbon Footprint Management
mRNA products often require ultra-cold storage. Expanding regional cold-chain networks with energy-efficient infrastructure will be critical to reducing emissions.
Regionalised Manufacturing to Reduce Logistics Emissions
Local production hubs across Asia-Pacific reduce long-distance shipping, mitigate supply disruption risks, and lower carbon impact associated with global distribution.
Strategic Insight: By 2030, sustainability performance may influence partnership selection, government funding eligibility, and export competitiveness within APAC.
STRATEGIC RECOMMENDATIONS FOR APAC
2030 ROADMAP: APAC RNA MANUFACTURING DEVELOPMENT
FINAL ASSESMENT
APAC has made substantial progress toward RNA commercialisation.
The region possesses:
- Expanding GMP infrastructure.
- Growing clinical pipelines.
- Government-backed initiatives.
- Increasing CDMO capacity.
However, achieving uniform commercial-scale readiness requires:
- Regional supply chain development.
- Enhanced analytical capabilities.
- Platform standardisation.
- Regulatory collaboration.
If current investment trends continue, APAC is positioned to become a major global hub for RNA therapeutics manufacturing within the next decade.
Join RNA Therapeutics & Manufacturing Asia 2026
Share With Your Network
